Celldex Therapeutics Inc., of Hampton, N.J., said in its first-quarter earnings that it is discontinuing development of CDX-014, an antibody-drug conjugate (ADC) in early phase I development in renal cell and clear cell ovarian carcinomas, and CDX-1401, an NY-ESO-1 antibody fusion protein being explored in investigator-sponsored and collaborative studies.